First Health United is a non-profit organization based in The Netherlands. We are a fully independent spin off of the company First Health Pharmaceuticals, who transferred the largest part of its antivirus development pipeline to our non-profit foundation.
Our Mission
We develop revolutionary new antiviral agents based on an existing portfolio of highly active pharmaceutical compounds that was granted to our organization by our sponsor First Health Pharmaceuticals.
Pharmaceutical Research
A Revolutionary Approach

First Health United to participate at AIDS2018
First Health Pharmaceuticals and First Health United Foundation are going to participate at AIDS2018, the 22nd International AIDS Conference on HIV and AIDS, which will take place in Amsterdam, the Netherlands, from 23 to 27 July 2018.
Social Responsibility
First Health Pharmaceuticals took its Social Responsibility very serious when it donated the largest part of its antivirus pipeline to First Health United. The decision is testimony to the fact that profit maximisation is clearly not the only goal of the company and that Social Responsibility is a driving force within the First Health group.
We are Different
Most non-profit organisations work at a national level, gravitating towards basic research in their country of origin. First Health United is different: We collaborate with whatever university is a leader in our field of research, regardless if it is in the Netherlands, China, Italy or the USA.
Your contribution will save lives
You can contribute to the development and non-profit distribution of tangible new pharmaceuticals.
You can help saving tens of thousands of lives each year. Your donations will directly support First Health United Foundation’s commitment of development and non-profit distribution of tangible new pharmaceuticals that are effective against crippling infectious viral diseases.
Besides the Dengue Project, First Health United is investigating cures for other viral diseases. It also offers the possibility to sponsor specific scholarships targeting the development of new antivirus agents against a specific disease.